^
Association details:
Biomarker:KRAS G12D
Cancer:Non Small Cell Lung Cancer
Drug Class:PD1 inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer

Published date:
07/11/2022
Excerpt:
A clinical cohort of 74 NSCLC patients that harbored KRAS mutations and received anti-PD-1/PD-L1 monotherapy…the NSCLC patients with KRAS-G12D mutations had significantly shorter progression-free survival (PFS) than those with other point mutations (P = 0.006; Figure 1B).
DOI:
https://doi.org/10.1002/cac2.12327